Loading...
•
Mar 31, 2023
Precigen Q1 2023 Earnings Report
Precigen's financial results for Q1 2023 were announced, featuring advancements in clinical programs and a strengthened financial position.
Key Takeaways
Precigen reported its Q1 2023 financial results, highlighting the successful closing of a public offering, regaining rights to CD19 and BCMA targets, and advancements in UltraCAR-T portfolio. The company is focused on strengthening its financial footing while advancing promising programs.
Presented positive Phase 1 clinical data for PRGN-2012 AdenoVerse™ immunotherapy in RRP, demonstrating a favorable safety profile and significant reduction in surgeries.
Completed enrollment in the Phase 2 study of PRGN-2012 in RRP.
Dosed the first patient in the Phase 1/1b study of PRGN-3007, a next-generation UltraCAR-T® in advanced ROR1+ hematological and solid tumors.
Regained exclusive rights to validated CAR-T targets, CD19 and BCMA, to enable development and commercialization of UltraCAR-T®.
Forward Guidance
Precigen anticipates a solid cash runway to support priorities into late 2024, driven by financial discipline, a public offering, and early debt retirement.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...